The funds will reimburse AcelRx for development, manufacturing and clinical costs necessary to prepare for and complete the planned Phase 2 dose-finding trial and prepare to enter Phase 3 development.
The drug, ARX-04, features sufentanil, a high therapeutic index opioid in AcelRx’s proprietary NanoTab technology, enabling rapid sublingual absorption when the NanoTab is placed under the tongue.
Read the AcelRx release on pain medication.
Related Articles on Opioids for Treatment of Pain:
6 Steps Pain Physicians Can Take to Curtail Misuse of Opioids
Opioid Pain Medications Drive “Epidemic” of Unintentional Drug Overdose Deaths
Daily Dose Strongly Associated With Opioid-Related Mortality Among Nonmalignant Pain Patients
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.